Manal Abunimeh

Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease

Paul J. Pockros, K. Rajender Reddy, Parvez Mantry et al. · Gastroenterology · 2016 · 277 citations · Full text

LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study

Paul J. Pockros, K. Rajender Reddy, Parvez Mantry et al. · Journal of Hepatology · 2015 · 74 citations

Hcv Gt1 Infection, Viral Hepatitis, Medicine +10

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

Eric Lawitz, Robert Flisiak, Manal Abunimeh et al. · Liver International · 2019 · 62 citations

Ombitasvir/Paritaprevir/R, Dasabuvir, and Sofosbuvir Treatment of Patients with HCV Genotype-Infection who Failed a Prior Course of DAA Therapy: The Quartz-I Study

F. Poordad, Michael Bennett, Thomas Sepe et al. · Journal of Hepatology · 2016 · 27 citations

Viral Persistence, Viral Hepatitis, Hcv Genotype-infection +10

Efficacy and safety results of patients with <scp>HCV</scp> genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (<scp>QUARTZ II</scp>‐<scp>III</scp>)

Stephen D. Shafran, Douglas W. Shaw, Mariem Charafeddine et al. · Journal of Viral Hepatitis · 2017 · 14 citations